NovaBiotics Shortlisted for the Grampian Award for Innovation
NovaBiotics Ltd, the Aberdeen-based, clinical-stage biotechnology company has been shortlisted for The Grampian Award for Innovation at the 2014 Grampian Awards for Business Excellence which will be held on the 26th of June at the Mercure Aberdeen Ardoe House Hotel.
The Grampian Award for Innovation is awarded to an individual or a business that demonstrates innovation at the core of their current or future success. The winner will be able to clearly articulate the innovative steps they have taken and how the resulting products or services have disrupted the current marketplace or have the potential to do so.
NovaBiotics was shortlisted for its ground-breaking R&D in the anti-infective space which could meet the needs of patients worldwide. NovaBiotics is leveraging its peptide technology platform and drug design expertise to generate a totally novel class of antimicrobial therapies that not only have the potential to meet the need for safer, more effective antifungal and antibacterial treatments but also have no or very low risk of drug resistance development.
Dr Deborah O’Neil said: “The North East is populated with outstanding entrepreneurs and businesses and NovaBiotics is delighted to be recognised for its innovative work by being put through to the final stage of the Awards.”
The 2014 Grampian Awards for Business Excellence, hosted by Enterprise North East Trust, take place each year and commend enterprise by selecting and rewarding entrepreneurial companies and individuals that are capable of leading the future prosperity of Grampian.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...